| Name | Title | Contact Details |
|---|---|---|
Brian Crosby |
VP of Specialty Physicians and Product Lines | Profile |
The Word & Brown Companies, headquartered in Orange, Calif., provides services through more than 50,000 brokers to nearly 60,000 employers with more than 6 million eligible employees. During its more than 20-year-span, The Word & Brown Companies has become the nation’s recognized leader in developing and offering innovative technology, health benefit plan models, and sophisticated employee benefits services to companies of all sizes. The Word & Brown Companies includes: Word & Brown General Agency, the leader in developing and distributing health benefit plan models and solutions to licensed brokers in California and Nevada; CHOICE Administrators, the nation’s leader in developing and administrating employee-choice health benefit programs; CONEXIS, providing benefits solutions to clients nationwide, with expertise in COBRA and HIPAA administrative services, Direct Bill Services, and Flexible Benefits Administration, including Flexible Spending Accounts (FSA) and Section 132 Commuter Benefits; Quotit Corporation the leading Internet application service provider for the health insurance/employee benefits industry; and HealthCompare, which works with brokers and carriers to help individuals and families easily research, compare, buy, and enroll in the right health insurance plan at the right price.
National HealthCare Services is a Long Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VNUS Medical Technologies, Inc. is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Delphi Behavioral Health Group is a growing network of addiction treatment facilities that provide the full spectrum of care to those who are ready to start on the road to addiction recovery.
EyePoint Pharmaceuticals is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company`s pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert`s proven intravitreal drug delivery platform has been safely administered to thousands of patients` eyes across four U.S. FDA-approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.